Allarity Therapeutics Inc 宣布,其用于Stenoparib的DRP®伴随诊断技术已获得一项关键的美国专利授权。 此项被授予的专利保护期将延长至2042年4月。此外,该公司就Stenoparib DRP在欧洲和澳大利亚的专利保护也已确立,有效期至2039年。
Allarity Therapeutics Inc 宣布,其用于Stenoparib的DRP®伴随诊断技术已获得一项关键的美国专利授权。 此项被授予的专利保护期将延长至2042年4月。此外,该公司就Stenoparib DRP在欧洲和澳大利亚的专利保护也已确立,有效期至2039年。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.